NSE: TORNTPHARM | BSE: 500420

Expensive Rocket

Download real time

4896.50 -108.50 (-2.17%)

236.0K NSE+BSE Volume

NSE 21 Aug, 2026 3:31 PM (IST)

186,247.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Search Inside the pdf :

Torrent Pharmaceuticals Ltd.

31 Jul 2026

4896.50

-2.17%

Strong tailwinds underway

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharma’s (Torrent) strong performance in Q1FY27 was led by traction in India and currency benefits. The base business in India grew a robust 19%, led by traction in its top 10 brands and the semaglutide launch (INR 500mn revenue).

Torrent Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Torrent Pharmaceuticals Ltd.

31 Jul 2026

4896.50

-2.17%

India/US/currency benefits lead the charge

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered better-than-expected financial performance in 1QFY27, with 6%/9%/9% beat in revenue/EBITDA/PAT.

Torrent Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Torrent Pharmaceuticals Ltd.

01 Jul 2026

4896.50

-2.17%

GLP-1 set to boost branded generic growth

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharma’s (Torrent) dominance in cardio-diabetes therapies, coupled with its varied portfolio and a dedicated field force, has helped the company garner 34–35% volume market share in GLP-1 in India.

Number of FII/FPI investors decreased from 960 to 923 in Jun 2026 qtr

Torrent Pharmaceuticals Ltd.

25 Jun 2026

4896.50

-2.17%

TORRENT PHARMA

Hold: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent Pharmaceuticals Ltd is engaged in the research, development, manufacturing and marketing of generic pharmaceutical formulations.

Torrent Pharmaceutic.. has an average target of 4620.71 from 8 brokers.

Torrent Pharmaceuticals Ltd.

26 May 2026

4896.50

-2.17%

Torrent Pharma

Buy: Torrent Pharmaceuticals Ltd.

Target

ICICI Direct

About the stock: Incorporated in 1959, Torrent remains a key play in branded generics (~75% of sales) with strong India franchise and growing exports traction. While Branded franchisee comprises of India, Brazil and some export markets, the...

Torrent Pharma has gained 32.87% in the last 1 Year

Torrent Pharmaceuticals Ltd.

25 May 2026

4896.50

-2.17%

BP Equities Q4FY26 Result Update Torrent Pharmaceuticals Ltd.

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

...

Number of FII/FPI investors decreased from 960 to 923 in Jun 2026 qtr

Torrent Pharmaceuticals Ltd.

16 Feb 2026

4896.50

-2.17%

Steady India and currency drip into strong performance

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharma (Torrent) posted a strong show in Q3FY26, driven by its businesses in India (+13.7% YoY) and Brazil (27.5%). INR depreciation too played its part in boosting performance of exports.

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 4959.6

Torrent Pharmaceuticals Ltd.

16 Feb 2026

4896.50

-2.17%

BP Equities Q3FY26 Result Update Torrent Pharmaceuticals Ltd.

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

...

Torrent Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Torrent Pharmaceuticals Ltd.

14 Feb 2026

4896.50

-2.17%

DF/LATAM outperforms; Germany underperforms

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered a better-than-expected performance, with 3%/5%/10% beat on revenue/EBITDA/PAT in 3QFY26. Growth was aided by consistent superior execution in domestic formulation (DF)/LATAM, favorable currency benefits in the US, and a lower tax rate.

Torrent Pharma has gained 32.87% in the last 1 Year

Is Torrent Pharmaceuticals Ltd. worth buying?

163 Votes:

Buy 73.01%

Sell 16.56%

Hold 10.43%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf